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In osteoarthritis (OA), impairment of cartilage regeneration can be related to a defective 
chondrogenic differentiation of mesenchymal stromal cells (MSCs). Therefore, 
understanding the proteomic- and metabolomic-associated molecular events during the 
chondrogenesis of MSCs could provide alternative targets for therapeutic intervention. 
Here, a SILAC-based proteomic analysis identified 43 proteins related with metabolic 
pathways whose abundance was significantly altered during the chondrogenesis of OA 
human bone marrow MSCs (hBMSCs). Then, the level and distribution of metabolites 
was analyzed in these cells and healthy controls by matrix-assisted laser 
desorption/ionization mass spectrometry imaging (MALDI-MSI), leading to the 
recognition of characteristic metabolomic profiles at the early stages of differentiation. 
Finally, integrative pathway analysis showed that UDP-glucuronic acid synthesis and 
amino sugar metabolism were downregulated in OA hBMSCs during chondrogenesis 
compared to healthy cells. Alterations in these metabolic pathways may disturb the 
production of hyaluronic acid (HA) and other relevant cartilage extracellular matrix 
(ECM) components. This work provides a novel integrative insight into the molecular 
alterations of osteoarthritic MSCs and potential therapeutic targets for OA drug 






Articular cartilage is a connective tissue with a limited intrinsic capacity for repair, 
attributable to its avascular nature and low mitotic cell activity. Due to its poor healing 
response following injury, it is highly susceptible to osteoarthritis (OA) (1). OA is 
currently considered a heterogeneous disease involving pathological changes in all joint 
tissues, including cartilage, synovium, subchondral bone, meniscus, and ligaments (2). 
Healthy and OA articular tissues contain mesenchymal stromal cells (MSCs) with 
chondrogenic capacity that may participate in the repair of cartilage lesions in OA (3, 4). 
Accordingly, articular tissues obtained from patients with meniscal injury and early OA 
are enriched in MSCs when compared to healthy (5, 6). These findings suggest that failure 
in articular cartilage regeneration may not be a result of limitations in the supply of MSCs, 
but could be related to a defective chondrogenic differentitation of MSCs during attempts 
to restore healthy cartilage homeostasis. Drugs able to stimulate the chondrogenic 
capacity of MSCs in the joint represent an attractive approach for developing 
chondroprotective treatments or disease-modifying osteoarthritis drugs (DMOADs) (7). 
In this regard, it has recently been shown in a surgically-induced OA rat model that 
specific small molecules, when administered directly into the joint space, are able to 
inhibit joint destruction through Wnt signaling pathway regulation, being thus candidates 
for a potential disease modifying therapy for OA (8). Therefore, the elucidation of the 
mechanisms governing the chondrogenic differentiation of MSCs can lead to the 
identification of novel molecular markers that could be used as targets for alternative 
DMOADs development.   
Proteomic approaches have been applied to increase knowledge of the differentiation 
processes of MSCs obtained from different tissues (9). For instance, label-free relative 
quantification strategies have recently been performed for the secretome and proteome 
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characterization of hBMSCs undergoing chondrogenesis (10, 11). However, label-free 
proteomic methods are less accurate, less precise, and less reproducible for protein 
quantification compared to those based on stable isotope labeling such as stable isotope 
labeling by amino acids in cell culture (SILAC) (12, 13). The latter is one of the most 
accurate quantitative mass spectrometry (MS) methods, because the differentially 
labelled samples are combined very early in the experimental workflow, which minimizes 
errors during sample handling (14-16). Hence, we previously applied quantitative 
proteomics based on SILAC to evaluate modulations in the intracellular protein profiles 
during chondrogenic differentiation of hBMSCs obtained from healthy donors (17).  
In addition to protein expression, metabolic pathway alterations have also been associated 
with the modulation of chondrogenesis. Glycolysis, mitochondrial respiration, and uronic 
acid pathways have recently been reported to be involved in adenine triphosphate (ATP) 
oscillations, which play an essential role in prechondrogenic condensation (18). Other 
studies have also detected changes in fatty acid synthesis and amino acid production 
during chondrogenic differentiation of 3D-cultured hBMSCs in alginate beads using 1H 
nuclear magnetic resonance spectroscopy (19). Thus, the global analysis of metabolic 
changes during chondrogenesis might also provide important information about the 
molecular mechanisms and potential markers of this process. 
For that reason, we previously identified and visualized by matrix-assisted laser 
desorption/ionization–mass spectrometry imaging (MALDI-MSI) different lipid species 
in micromasses (3D cell aggregate systems) obtained from hBMSCs undergoing 
chondrogenesis (20). While our preceding studies offered important insights about 
chondrogenesis in healthy circumstances, the proteomic and metabolomic analysis of 
hBMSCs from OA patients will increase our understanding of cartilage formation 
processes under pathological conditions. This can aid to identify new molecular 
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mechanisms and targets for therapeutic interventions. Here, we evaluated the 
characteristic proteomic and metabolomic changes of OA hBMSCs in a chondrogenic 
model. Using SILAC-MS, we found statistically significant alterations in 43 proteins 
during the chondrogenesis of hBMSCs obtained from OA patients. The analysis of 
metabolic changes studied by MALDI-MSI revealed substantial differences between OA 
and healthy hBMSCs before and after the early stages of differentiation, specifically 
implicating an alterated pentose/glucuronic pathway in OA. This knowledge may be 
instrumental for developing future therapies. 
 
Experimental Procedures 
Experimental design and statistical rationale 
The experimental design and statistical rationale for each of the proteomic and MALDI-
MSI experiments conducted in this work will be described more in detail in each 
subsection. The discovery phase of the proteomics study was performed on three different 
OA biological samples without technical replication. MALDI-MSI analysis was 
performed on three control and five different OA samples, with two technical replicates 
per condition.  
Human bone marrow specimens 
Bone marrow samples were obtained as trabecular bone biopsy specimens from femoral 
heads of OA patients (n=13) undergoing total hip replacement surgery, and donors with 
no history of joint disease (control, n=11). All tissue samples were provided by the Tissue 
Bank and the Autopsy Service at Hospital Universitario de A Coruña. OA patients were 
diagnosed following the criteria determined by the American College of Rheumatology 
(21). Informed consent was obtained from the patients before surgery. The study was 
approved by the local Ethics Committee (Galicia, Spain). Patient data collection including 
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demographic and clinical characteristics (age, weight, body mass index, etc.) are 
summarized in Supplemental Table S1.  
Cell labeling and chondrogenic differentiation 
hBMSCs were isolated and labeled as previously described (22). hBMSCs were firstly 
characterized based on their negativity for CD34 and CD45 and their positivity for CD73, 
CD90, CD105 and CD166 by flow cytometry and their differentiation potential towards 
cartilage, bone and adipose tissue (23, 24). Briefly, 5 × 104 cells were seeded in 
Dulbecco’s modified Eagle’s medium (DMEM) 4.5 g/L glucose deficient in arginine and 
lysine, supplemented with 10% dialyzed FBS, 2mM Lglutamine, and antibiotics, 
containing also 28 mg/L L-arginine-HCl−13C6
15N4 (Arg10) and 146 mg/L L-lysine-




(Lys0) (all from Silantes, Munich, Germany). Cells were subcultured every week until 
achieving 100% labeling. Cell viability and normal growth rates were assessed in the 
SILAC media supplemented with the different isotopes using a CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay (Promega, Wisconsin, USA) kit.  
SILAC-labeled cells populations were then cultured in 3D high-density pellet mass 
cultures or micromasses with chondrogenic differentiation medium containing 10 ng/ml 
TGF-β3 for 14 days. The micromass in vitro culture system employed to direct stem cell 
differentiation into the chondrogenic lineage has been extensively stardardized and 
characterized in our laboratory, maintaining cell viability and the synthesis of the 
extracellular matrix components under our experimental conditions (23-25).  
Micromasses were collected after 2 days and 14 days in culture, and stored at -80 °C until 
further analysis. hBMSCs employed in the proteomic analysis were obtained from 
femoral heads of three OA patients. For MALDI-imaging experiments, micromasses were 
embedded in 10% gelatin at 37 °C and immediately frozen at -80 °C. For these imaging 
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experiments, samples from five additional OA patients and three individuals with no 
history of joint disease were included. Additionally, gene expression assays were carried 
out using OA and control hBMSCs from independent experiments, five and eight, 
respectively.  
Immunohistochemical analyses of cell differentiation 
For chondrogenesis evaluation, micromass pellets were frozen in OCT embedding matrix 
(BDH Chemicals, Poole, U.K.) and cut at 4 μm with a cryostat (Leica Microsystems, 
Barcelona, SP) for immunohistochemical evaluation. Sections were immunostained with 
monoclonal antibodies against aggrecan (1:100, Abcam, Cambridge, UK), chondroitin-
6-sulphate (1:500, Abnova GmbH, Germany), keratan sulphate (1:100, Santa Cruz 
Biotechology), type II (1:200, Abcam, Cambridge, U.K.), type I (1:1000, Abcam, 
Cambridge, U.K.) and type X collagens (Sigma Aldrich, St. Louis, MO, USA). The 
peroxidase/DAB ChemMateTM DAKO EnVisionTM detection kit 
(Dako, Barcelona, Spain) was used. Setions were counterstained with hematoxilyn and 
mounted with Eukitt resin. The percentage of positivity of each inmunohistochemical 
assay was measured using ImageJ software (NIH, Bethesda, MD, USA). Three 
representative images were selected for each donor (control, n=5 and OA, n=4) and used 
for relative quantification. 
Sample preparation for MALDI-MSI 
Micromass sections (10µm) were obtained using a cryostat, mounted onto indium tin 
oxide (ITO), high conductivity slides (Delta Technologies, Stillwater, MN, USA) and 
stored at -80 °C until further analysis. Prior to matrix application, slides were placed in a 
vacuum dessicator at room temperature and defrosted for 20 min. A matrix solution of 10 
mg/ml of 9-aminoacridine (9-AA) (Sigma-Aldrich, Zwijndrecht, The Netherlands) 
dissolved in 70% ethanol was prepared. The matrix was then deposited onto the tissue 
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section surface using a HTX TM-Sprayer (HTX Technologies, LLC, North Carolina, 
USA). The complete loop of the sprayer (5 ml) was first flushed with the matrix solution 
and then applied to the sample surface. The matrix flow rate of the pump was 120 µl/min, 
the air pressure was set to 10 psi and a block temperature of 85 °C was chosen. The stage 
of the spraying device was moved at a speed of 1200 mm/min and the distance between 
the spray nozzle to the glass slide was set to 40 mm. Four layers of matrix were applied 
with 30 seconds of drying time between each pass in order to achieve homogeneous 
matrix coverage. In addition, the spray pattern was changed by an angle of 90° and 
adjusted with a line spacing of 3 mm. 
Protein extraction and in-gel digestion  
Proteins were extracted from the micromasses using a combination of a mix miller and a 
lysis buffer containing 6 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-base, as 
previously described (17). Total protein concentrations were determined using the 
Bradford assay (Sigma). Heavy (micromasses at day 14) and light (micromasses at day 
2) samples were then mixed in a 1:1 ratio according to the measured protein 
concentrations, and 15 µg of each mixed sample were resolved onto a 10% SDS-PAGE. 
The gel was stained with Coomassie blue, and 10 gel bands were excised. The gel pieces 
were washed with 50% acetonitrile (ACN) in a 25 mM ammonium bicarbonate solution 
until completely destained. Samples were then reduced with 10 mM dithiothreitol for 30 
min at 56 °C and alkylated with 54 mM iodacetamide for 10 minutes in the dark. 
Digestion was performed overnight with 6.66 ng/μl sequencing-grade modified trypsin 
(Promega, Madison, WI, USA) at 37 °C. Trifluoroacetic acid (TFA) (1% final 
concentration) was added to the peptide mixtures to stop the enzymatic reaction. Peptides 
were then extracted from the gel pieces with 50% ACN/0,1% TFA. Extracted peptide 
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mixtures were desalted and concentrated employing NuTips (Glygen, Columbia, MD, 
USA), dried in a speedvac and stored at -80 °C until LC-MS/MS analysis.  
Mass spectrometry analysis  
The peptide fractions were separated using reversed phase chromatography in a nanoLC 
system (Tempo, Eksigent, Dublin, CA, USA) by loading through a trap column into a 
C18 silica-based column (Integrafit C18, ProteopepTM II, 75 µm id, 10.2 cm, 5 µm, 300 
Å, New Objective, Woburn, MA, USA). Peptides were eluted at a flow rate of 350 nl/min 
during a 120-min linear gradient from 5 to 45% B (mobile phase B: 0.1% TFA 80% 
ACN), mixed with α-cyano-4-hydroxycinnamic acid matrix (3 mg/ml at a flow rate of 1.2 
μl/min) and deposited onto a MALDI plate using an automatic spotter (SunCollect, 
Sunchrome, Friedrichsdorf, Germany).  
Data acquisition was carried out using a 4800 MALDI-TOF/TOF instrument (AB Sciex, 
Foster City, CA, USA) with a 200-Hz repetition rate (Nd:YAG laser). MS full-scan 
spectra from 800 to 4000 m/z were acquired for each peptide-containing LC spots using 
1500 laser shots and a laser intensity of 3800 kV. After screening of all LC-MALDI 
sample positions in MS positive reflector mode, the fragmentation of automatically 
selected precursors was performed at a collision energy of 1 kV with a collision-induced 
dissociation (CID) gas (air). Up to 12 of the most intense ion signals per spot position 
with signal/noise ratio (S/N) above 80 were selected as precursors for tandem mass 
spectrometry (MS/MS) analysis, excluding common trypsin autolysis peaks and matrix 
peaks. The number of shots was 1800 for MS/MS, and the laser intensity was set to 4700 
kV. A second MS/MS was performed, excluding the precursors selected in the previous 
MS/MS run. Precursors with S/N >30 were selected to identify proteins that were not 
identified in the first MS/MS analysis. 
Proteomic data analysis 
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Proteomic data analysis was performed on three different OA biological replicates 
without technical replication. Data was acquired using 4000 Series Explorer v.3.7. 
Protein identification and quantification were carried out using ProteinPilot™ software 
v.4.0 (AB Sciex, Foster City, CA, USA). Each MS/MS spectrum was searched in the 
Uniprot/Swissprot database (UniProt 2015_05 release version containing 547,599 
sequences and 195,014,757 residues, with taxonomy restriction_Homo sapiens) using 
the Paragon Algorithm. The following ProteinPilot search parameters were used: 
sample type set as SILAC (Lys +6, Arg+10), oxidation of methionine residue as 
variable modification, iodoacetamide alkylation of cysteine residue as a fixed 
modification and a maximum of one missed cleavage allowed for trypsin. The 
ProteinPilot software also calculated a confidence percentage, the Unused score, which 
reflects the probability of a hit being a false positive. Data were also normalized for 
loading error by bias correction. Searches against a concatenated database containing both 
forward and reversed sequences allowed the false discovery rate to be kept at 1%. 
Common contaminants such as trypsin autolysis peaks and matrix ion signals were 
excluded from the analysis. The theoretical ions and the peaks were matched using the 
same tolerance used by the Paragon Algorithm search. The tolerance used for matching 
is based on information about the mass accuracy of the instrument chosen in the Paragon 
Method dialog box. We considered statistically significant only those changes with a p 
value <0.05 and ±20% change in expression from day 2 to day 14. GO enrichment 
analysis on the set of modulated proteins was performed using Uniprot database. 
MALDI-FT-ICR-MSI experiments 
Sprayed tissue sections were optically scanned and imported into FlexImaging 4.1 
software (Bruker Daltonik GmbH, Bremen, Germany) to define the area of the sample to 
be imaged. Tissue sections were then analyzed using a Bruker 9.4 T solariX FT-ICR mass 
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spectrometer equipped with a SmartBeam II Nd:YAG laser operated with the MALDI 
source. Samples from each donor were analyzed in duplicate. The instrument external 
calibration was performed using a solution of red phosphorous (Sigma-Aldrich 
(Zwijndrecht, The Netherlands) ranging between mass/charge (m/z) 50–1000 Da prior to 
MALDI-FT-ICR-MSI analysis. The analytical parameters for the on-line calibration were 
as follows: mode, linear; threshold (abs), 1 × 105; mass tolerance, 10 ppm; reference 
masses m/z 193.07602 (9-AA), m/z 346.05471 (AMP), m/z 426.02104 (ADP) and m/z 
505.98737 (ATP). Data were acquired at a spatial resolution of 30 µm using FlexControl 
software. Each mass spectrum was obtained from a single scan of 200 laser shots using 1 
million data points in negative ionization mode within a mass range of m/z 100–1000 Da, 
a laser power of 22% and a frequency of 2000 Hz. MALDI-MSI images of differentially 
expressed metabolites were generated with FlexImaging 4.1 software (Bruker Daltonik 
GmbH, Bremen, Germany). These images were also obtained with a mass window of ± 
0.001 Da and normalized using root means square (RMS). Following MSI analysis, the 
slides were rinsed in 70 % ethanol to remove the matrix. Then, the slides were 
subsequently stained with hematoxylin and eosin (H&E). Optical images of all stained 
tissue sections were acquired using a MIRAX desk scanner (Zeiss, Gottingen, Germany) 
in order to spatially co-relate the ion distribution to histology. 
Multivariate statistical analysis of MALDI-FT-ICR-MSI data 
Principal component analysis (PCA) and discriminant analysis (DA) were employed to 
look for spectral similarities and differences between the samples collected at day 2 and 
14, using an in-house built ChemoneTricks toolbox for MATLAB version 2014A (The 
MathWorks, Natick, MA, USA). The MS raw data were first converted to the MATLAB 
format. Then, all the spectra generated in the MSI experiments from the two time points 
all OA and control donors were combined and peak-picked prior to PCA. Peak picking 
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was performed with the in-house-built PEAPI software to reduce the data set to a size that 
enables the computational methods needed (26). The number of principal components 
used as input for DA was limited to one quarter of the total number spectra to prevent 
overfitting of the DA model. PCA-DA was applied independently to the biological and 
technical replicates in order to evaluate the reproducibility among donors. After data 
analysis, m/z values were selected for further identification. Metabolites with DF1 score 
loadings >±5 according to PCA-DA analysis, and a p value <0.05 by the Mann-Whitney 
test were considered significantly altered. 
Metabolite identification by tandem mass spectrometry  
Tandem mass spectrometry (MS/MS) was performed using CID in an ion trap mass 
analyser from the MALDI-LTQ-Orbitrap Elite mass spectrometer directly on the 
micromass sections using a collision energy of 38 and an isolation width of 0.7 Da. Data 
were analyzed using Xcalibur software 2.3.26 (Thermo Fisher Scientific, Bremen, 
Germany). Identifications were based on the high mass accuracy and resolution of the 
precursor mass and MS/MS analyses in comparison to metabolite and lipid databases, 
such as the Human Metabolome Database (HMDB) http://www.hmdb.ca (27), METLIN 
(http://metlin.scripps.edu) (28) and LipidMaps (www.lipidmaps.org) (29). For the 
assignments, 5 ppm mass accuracy was selected as the tolerance window. If MS/MS 
spectra were not available in the databases or did not match with the expected theoretical 
spectra, metabolites matching the precursor mass in either HMBD, METLIN or 
LipidMaps were subjected to manual interpretations to attempt to match experimental 
MS/MS spectra with expected fragment structures. Metabolite assignments, with their 
corresponding mass errors and MS/MS structural validation, are summarized in 
Supplemental Table S2. As an example, we assigned the peak at m/z 540.0474 to the 
[M-H2O-H]
- ion of adenine diphosphate (ADP)-ribose based on the accurate mass 
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difference (1.1 ppm) and the interpretation of the MS/MS spectrum following collision-
induced dissociation of ions at m/z 540.0533 (Supplemental Figure S1).  
Enrichment, pathway and integrative metabolic analysis 
The differentially expressed metabolites from the comparative analyses of OA vs. control 
and 2 d vs. 14 d were further subjected to enrichment and pathway analysis using 
MetaboAnalyst software 4.0 (30). Pathway analysis combines the results obtained from 
enrichment and topology analysis to visualize the most relevant metabolic processes 
involved in the studied conditions. MetaboAnalyst is based on different databases, 
including the Kyoto encyclopedia of genes and genomes (KEGG) (31), small molecule 
pathway database (SMPD) (32) and HMBD for the identification of relevant metabolic 
pathways. Finally, we performed an integrated analysis combining metabolomic and 
protein expression studies. In this analysis, both metabolites and genes/proteins were 
mapped to KEGG metabolic pathways for over-representation analysis (ORA) and 
topology analysis. Topology analysis uses the structure of a given pathway to evaluate 
the relative importance of the matched proteins/metabolites based on their relative 
location. The algorithms used for ORA and topology analysis were the hypergenometric 
test and betweenness centrality, respectively. Pathway significance is determined from 
enrichment analysis and the impact value is based on topology analysis. Pathways were 
considered significant when the p value calculated from the enrichment analysis were 
≤0.05.  
RNA extraction and quantitative real-time PCR assays 
Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA), 
according to the manufacturer’s instructions. After RNA extraction, 1 µg of RNA was 
reverse transcribed into complementary DNA (cDNA) using SuperScript™ VILO™ 
cDNA synthesis kit in accordance with the manufacturer’s instructions, and was analyzed 
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by quantitative real-time PCR (qRT-PCR). The reactions were carried out in 96-well 
plates in duplicate using a LightCycler 480-II Instrument (Roche, Mannheim, Germany) 
with TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA, USA). 
Primers for UTP-glucose-1-P-uridylyltransferase (UGP2), UDP-glucose dehydrogenase 
(UGDH) and Ribosomal protein L13a (RPL13a) were designed using the Universal Probe 
Library tool from the Roche website. Data were analyzed using Qbase+ software 
(Biogazelle, Gent, Belgium). Gene expression was normalized to the housekeeping gene 
RPL13a (selected after GeNorm expression stability assesment) and expressed as the x-
fold change relative to day 2. Sequence primers, probes and PCR conditions are given in 
Supplemental Table S3. 
Statistical analysis 
A p value < 0.05 was considered statistically significant and statistical tests were two-
sided. Data were analyzed using GraphPad Prism software 7.0. and presented in the figure 
legends or text as mean ± standard error of the mean (SEM). Two-group comparisons 
(day 2 vs day 14) were carried out using the Mann-Whitney test with significant values 
indicated as follows: *p value <0.05, **p value <0.01, ***p value <0.001, n.s. not 
significant.   
Results 
Characterization of control and OA hBMSCs undergoing chondrogenic 
differentiation 
hBMSCs derived from normal individuals and OA patients were pelleted and cultured in 
a chondrogenic differentiation medium for 14 days. To confirm chondrogenic induction 
of hBMSCs, well-known chondrocyte markers were assessed using 
immunohistochemical analyses. In line with previous studies (17, 22) we observed the 
upregulation of aggrecan (Agg), chondroitin-6-sulfate (CH6S) and keratan sulfate (KS) 
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by chondrogenic factors at day 14 compared to day 2, and these differences were 
statistically significant (*p value <0.05 (Agg and KS); ***p value <0.001(CH6S)), 
demonstrating the chondrogenic differentiation of normal hBMSCs under our culture 
conditions (Figure 1A-C). OA hBMSCs also showed statistically significant higher 
expression levels of CH6S and KS at day 14 of chondrogenesis (*p value <0.05). 
However, the expression levels of KS and Agg were notably lower compared to control 
hBMSCs at day 14 (*p value <0.05). Immunohistochemistry (IHC) results for collagen 
alpha-1 (II) chain (COL2A1) were also positive at day 14 for both control and OA 
hBMSCs (Figure 1D), although there were not statistically significant differences 
between the two time points assessed. Additionally, the expression of collagen alpha-1 
(I) chain (COL1A1), considered as a fibrocartilage/dedifferentiated chondrocyte marker, 
was greatly increased in OA (*p value <0.05) but not in control micromasses during 
chondrogenesis (Figure 1E). Finally, the IHC analysis demonstrated the higher presence 
of collagen alpha-1 (X) chain (COL10A1), considered as the standard marker for 
chondrocyte hypertrophy, within OA cell pellets at day 14 compared to control samples 
(Figure 1F), which indicates an early hypertrophic phenotype of OA hBMSCs in 
comparison with control cells.  
Differentially expressed proteins during the chondrogenesis of OA hBMSCs. 
To analyze and quantify protein changes occurring during chondrogenesis, 
undifferentiated (day 2) and differentiated (day 14) hBMSCs obtained from OA patients 
(n=3) were compared using SILAC-MS. The experimental workflow (Supplemental 
Figure S2) for the proteomic profiling of chondrogenic-induced hBMSCs led to the 
identification of 281 proteins (Supplemental Table S4), of which 43 proteins displayed 
statistically significant (±20% change; p value < 0.05) quantitative differences between 
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the two stages of chondrogenesis (Table 1). Detailed information of the identified 
proteins, with their corresponding peptides, is shown in Supplemental Table S5.  
From these 43 proteins, 33 were significantly increased and 10 were significantly 
decreased. The upregulated proteins include several typical structural proteins of the 
cartilage ECM, including perlecan (33), the three alpha chains of type VI collagen (34) 
or tenascin (35), and also many different glycolytic enzymes, such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), phosphoglycerate kinase 1 (PGK1), and 
triosephosphate isomerase (TPI1). The downregulated proteins included cytoskeleton-
related proteins, such as tropomyosin alpha-4 chain (TPM4), talin-1 (TLN1), and 
transgelin (TAGLN).  
To further elucidate the molecular mechanisms and related biological functions involved 
in chondrogenic differentiation of OA hBMSCs, we classified the set of 43 differentially 
abundant proteins according to their biological process using the Gene Ontology (GO) 
database (Supplemental Figure S3). The 33 proteins increased at the advanced stage of 
differentatiton (day 14) are involved in three main GO biological processes: (A) 
metabolism, including glycolysis (GAPDH, PGAM1, PGK1, TPI1, LDHA), glucuronate 
interconversion (AKR1B1, UGDH, UGP2), and the pentose phosphate pathway (TKT); 
(B) ECM organization (ANXA2, COL6A1, COL6A2, COL6A3, TNC); and (C) 
regulation of transcription (H2AFJ, HIST1H2BC, HIST1H4A). Inversely, proteins 
decreased at day 14 are mainly related with (A) cytoskeleton reorganization (TLN1, 
TPM4, TAGLN); (B) regulation of transcription (RNH1); and (C) protein synthesis, 
folding and transport (EEF2, SERPINH1). 
Metabolic changes in OA chondrogenesis compared to healthy controls. 
Since more than 45% of the differentially abundant proteins quantified by SILAC are 
involved in glycolysis and other metabolic processes, we then investigated the metabolic 
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profile of OA hBMSCs undergoing chondrogenesis and compared it to cells from healthy 
donors as controls. The metabolite levels and distribution were analyzed by MALDI-
Fourier transform-ion cyclotron resonance-MSI in cryosections of control (n=3) and OA 
(n=5) micromasses at day 2 (undifferentiated) and day 14 (early differentiated stage).  
Combined multivariate statistical analysis -in particular principal component analysis 
(PCA) and discriminant analysis (DA)- were performed on the resulting spectra that were 
acquired in the m/z range 100–1000 Da and applied independently to controls and OA 
samples. These analyses revealed that the metabolic profile of micromasses collected at 
day 2 is markedly distinct from that of micromasses at day 14 in both control (Figure 2A-
B) and OA conditions (Figure 2C-D). Initially, we observed that healthy and diseased 
cells exhibited a similar metabolic profile at day 2, presenting a higher abundance of 
nucleotides such as UMP, UDP and UDP-N-Acetyl-glucosamine (UDP-GlcNAc). 
However, they exhibited marked metabolic differences at day 14. For instance, increased 
levels of the sugar phosphate dihydroxyacetone phosphate (DHAP) and cholesterol 
sulfate were specific to healthy chondrocyte-like cells (Figure 2B, positive loadings), 
whereas several sugar nucleotides such as ADP-ribose and UDP-glucose, as well as fatty 
acids such as oleic acid, stearic acid and arachidonic acid, were specific to OA 
chondrocyte-like cells at 14 days of chondrogenic differentiation (Figure 2D, positive 
loadings, Supplemental Table S2). We identified 35 metabolites in OA samples that 
showed significant discrimination between days 2 and 14 (Figure 3, p < 0.05). Finally, 
to determine which metabolites were specific to healthy and OA hBMSCs during 
chondrogenic differentiation, a multivariate statistical analysis was then applied to all 
samples (Figure 2E-F). As illustrated in the frequency plot of Figure 2E, the second 
discriminant function (DF2) showed a clear difference between control and OA samples 
according to their metabolic composition. Based on their loadings, the metabolites 
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discriminating between control and OA were mainly nucleotides, sugar species and 
phosphatidic acid–related molecules (Figure 2F). On the one hand, the metabolic profile 
of the control samples (Figure 2F, positive loadings) included several PA-related 
metabolites, such as the lysophosphatidic acid LPA(18:0), the cyclic phosphatidic acids 
cPA(18:1) and cPA(18:0), and the phosphatidic acids PA(16:1_18:0), PA(18:0_18:2) and 
PA(18:0_18:1). On the other hand, the characteristic OA metabolic profile confirmed an 
abundance of nucleotides including ADP, UMP and UDP; several fatty acids such as oleic 
and stearic acid; certain sugar species, such as glucose monophosphate, N-Acetyl-
glucosamine-phosphate (GlcNAc-P), ADP-ribose and UDP-GlcNAc; and specific 
phospholipids such as phosphatidylinositol (PI) and phosphatidylglycerol (PG) species 
(Figure 2F, negative loadings). 
Pathway analysis shows alterations of five differential metabolic processes in OA 
hBMSCs compared to controls. 
Using MetaboAnalyst software, the functional role of these metabolites was determined 
by pathway analysis (Figure 4A and B). All metabolic pathways that were identified for 
control and OA samples are provided in Supplemental Table S6 and Supplemental 
Table S7. In both control and OA samples, purine and pyrimidine metabolism pathways 
were significantly altered during chondrogenesis (Figure 4A and B; p < 0.003). Five 
additional metabolic pathways were significantly modulated specifically in OA samples 
(Figure 4B; p < 0.05), which included galactose metabolism, amino sugar and nucleotide 
sugar metabolism, starch and sucrose metabolism, glycolysis or gluconeogenesis, and 
glycerolipid metabolism.  
To further elucidate the metabolic pathways involved in normal and OA hBMSCs 
undergoing chondrogenic differentiation, we also performed an integrative pathway 
analysis using the datasets from the significantly modulated proteins and metabolites. 
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This analysis took into account the total number of metabolites/proteins that match with 
a particular pathway (enrichment analysis) and the structure of the network, considering 
the position of the molecules inside the pathway (topology analysis). For the control 
pathway analysis, we integrated 17 metabolites (Supplemental Figure S4) with 51 
known proteins that had shown statistically significant quantitative alterations in control 
hBMSCs undergoing chondrogenesis (17). In the analysis of OA samples, we combined 
35 metabolites (Figure 3) with the 43 proteins significantly modulated in OA hBMSCs 
between the two time points of chondrogenesis (Table 1). The glycolysis pathway was 
statistically significant (p value < 0.004) in both control (Figure 4C) and OA (Figure 
4D) samples. Other pathways involved in the chondrogenic differentiation of healthy cells 
were galactose metabolism and fructose/mannose metabolism, but they were not 
significant (Supplemental Table S8). In contrast, five pathways were significantly 
altered (p value = 0.05) in OA hBMSCs undergoing chondrogenesis: pentose and 
glucuronate interconversions; galactose, starch, and sucrose metabolism; amino sugar and 
nucleotide sugar metabolism; and biosynthesis of unsaturated fatty acids (Figure 4D and 
Supplemental Table S9).  
Alteration of the glucuronic acid synthesis pathway in OA hBMSCs undergoing 
chondrogenesis 
Given our finding that pentose and glucuronate interconversion (KEGG pathway 
map00040) is one of the main altered metabolic pathways during the chondrogenesis of 
OA hBMSCs (Figure 4D), we investigated the correspondent substrates by MALDI-MSI. 
The main findings of this analysis are illustrated in Figure 5. In this pathway, UDP-
glucose - a key intermediate in the formation of UDP-glucuronic acid - is synthesized 
from glucose monophosphate (GP) and UTP in a reaction catalyzed by UTP-glucose-1-
phosphate uridylyltransferase (UGP2). Our proteomics data (Table 1) showed a 
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significant increase in UGP2 (p value < 0.05) at day 14 compared with day 2, which 
correlates with reductions in levels of glucose monophosphate (Figure 5A) and UTP. 
UDP-glucose is then oxidized by UDP-glucose 6-dehydrogenase (UGDH) to generate 
UDP-glucuronic acid (Figure 5B). Remarkably, we observed in the proteomic analysis a 
significant reduction in UGDH day 14 compared to day 2 (Table 1, p value < 0.03), which 
may contribute to the significant accumulation of UDP-glucose at day 14 that can be 
detected in the micromass core at day 14 (Figure 5B). Although UGP2 was significantly 
increased at the protein but not the mRNA level (Figure 5F), we did detect a significant 
down-regulation of UGDH at day 14 specifically in OA hBMSCs (Figure 5G, p value ≤ 
0.05). Also within this pathway, GlcNAc-P is derived from glucose monophosphate and 
converted to UDP-GlcNAc. Both GlcNAc-P and UPD-GlcNAc levels were decreased in 
the micromasses collected at day 14 compared to day 2 (Figure 5D-E). This indicates a 
downregulation of the amino sugar nucleotide metabolism during the chondrogenic 
differentiation of OA hBMSCs. Altogether, these data suggest a reduction in the synthesis 
of UDP-glucuronic acid and UDP-GlcNAc during the chondrogenic differentiation of OA 
cells that could affect HA synthesis and, as a consequence, the production of other key 
glycosaminoglycans (GAGs) and proteoglycans (PGs) from the cartilage ECM.  
A comparison of metabolite ion maps and the H&E stainings highlighted the distinct 
regional distribution of glucose monophosphate. We observed that OA micromasses 
collected at day 2 presented higher levels of glucose monophosphate in the micromass 
core, whereas this metabolite showed a higher abundance in the surrounding cells of the 
micromass at day 14 (Figure 5A). Another glycolytic intermediary metabolite, such as 
DHAP, was also mainly distributed in the cells of the micromass core at day 14 
(Supplemental Figure S5). These findings suggest that, at day 14, the hBMSCs that are 
localized in the core have a higher glycolytic activity. This leads to an increased glucose 
23 
 
consumption compared to those hBMSCs localized in the peripheral areas of the 
micromasses.  
Undifferentiated OA hBMSCs have an altered pentose phosphate pathway. 
Once observed the metabolic pathways involved during the chondrogenesis of control 
and OA hBMSCs, we next aimed to determine other specific metabolites potentially 
altered before the beginning of chondrogenesis. With this objective, we compared their 
metabolic profiles at the undifferentiated stage (day 2). The levels of thirty-two 
metabolites were distinct between OA and controls at this time point (Supplemental 
Table S10). Among these, 10 were classified as nucleotides, 6 sugar phosphates, 5 
phosphatidic acid (PA)-related metabolites, 3 inositol-related metabolites, 2 fatty acids, 
and 1 sugar nucleotide. Finally, 15 phospholipid species were also identified. The 
statistical analysis of these data revealed that undifferentiated hBMSCs from OA patients 
contained higher levels of sugars such as inositol phosphate, glucose monophosphate, 
fructose 1,6-bisphosphate (Fru-1,6-P2), and ribose 5-phosphate compared to control cells 
(Supplemental Figure S6). 
Finally, we carried out a metabolite set enrichment analysis (MSEA) to identify which 
pathways were affected at this early chondrogenic differentiation stage. Our results 
revealed 20 enriched pathways (Supplemental Figure S7), of which 4 were significantly 
upregulated in OA (p value <0.02): the pentose phosphate pathway (PPP), Warbur effect, 
lactose synthesis and gluconeogenesis. Next, we performed a metabolic pathway analysis 
using MetaboAnalyst to characterize the functional role of these metabolites and to 
estimate the node importance within the pathways. According to this analysis, we 
confirmed the finding that purine metabolism and the PPP were significantly altered (p 
value < 0.025) in OA hBMSCs compared to controls at day 2 (Supplemental Figure S7, 
Supplemental Table S11). The intensity and spatial distribution of several metabolites 
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involved in the PPP in OA and control micromass sections obtained at day 2 were 
examined using FlexImaging software (Supplemental Figure S8). Among these 
metabolites, ribose-5-phosphate and ribose 1,5-bisphosphate were differentially 
distributed across the micromass sections, with a relative higher intensity in the peripheral 
cells of the control micromasses. On the contrary, both metabolites were primarily 
detected in the cells located in the core of OA micromasses, suggesting a higher degree 
of proliferation in this area. 
Discussion 
Drugs stimulating the in vivo induction of chondrogenesis in MSCs have been suggested 
as a promising therapeutic approach for osteoarthritis treatment (36), as they may 
contribute to overcome the restricted regenerative capacity of articular cartilage. In order 
to provide novel targets for the development of DMOADs, proteomic and metabolomic 
approaches have been combined to identify alterations in metabolic pathways underlying 
the early phases of cartilage formation in an in vitro 3D model of osteoarthritic hBMSCs 
and healthy controls. Initially, the chondrogenic differentiation of control and OA 
hBMSCs in our model was evaluated using IHC assays. Although a higher expression of 
GAGs such as CH6S and KS was found in both healthy and diseased cellular models at 
day 14 of chondrogenesis, OA hBMSCs did also show a higher hypertrophic/fibrotic 
phenotype at the differentiated chondrogenic stage. MSC hypertrophy is characterized by 
an increase in cell volume, expression of collagen type X, matrix metalloproteinases and 
alkaline phosphatase activity (37). In addition, MSCs with hypertrophic phenotype 
express and produce collagen type I preferentially over collagen type II (38), which is 
indicative of fibrocartilage instead of hyaline cartilage formation. Therefore, promoting 
chondrogenic differentiation while preventing hypertrophy of chondrogenic MSCs is 
essential for the application of MSCs in strategies for cartilage regeneration. Accordingly, 
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the observed differences support the hipothesis of molecular alterations underlying the 
MSCs differentiation in OA. 
In an attempt to elucidate these derangements, a SILAC strategy was carried out to 
quantitatively describe the intracellular protein profiles of OA hBMSCs undergoing 
chondrogenic differentiation. Fourty-three proteins were altered with statistical 
significance between two early steps of chondrogenesis, day 2 and day 14 (Table 1). 
From this subset of proteins, the largest functional group included those involved in 
metabolic processes, an essential topic to understand chondrogenesis, cartilage 
physiology and pathophysiology (39). All of these proteins were increased at day 14 of 
chondrogenesis, except for UGDH. Moreover, most of the modulated proteins were 
involved in the glycolysis pathway, indicating an enhanced glycolytic activity induced by 
chondrogenic differentiation. This is consistent with the glycolytic nature of cartilage and 
is in agreement with previously reported higher rates of glycolysis following 
chondrogenic differentiation, when compared to proliferative MSCs (40); (41). All these 
data provide support to the key role of metabolic changes, particularly an enhancement 
of the glycolytic pathway, in the regulation of hBMSCs chondrogenesis. Together with 
our previous published data about proteomic changes of healthy hBMSCs undergoing this 
process, it can be concluded that a shift towards glycolysis is a common metabolic feature 
in the chondrogenesis of both OA and control hBMSCs. This also points out that early-
differentiated cells mainly rely on glycolysis as an energy source.  
Metabolomic analyses have recently been employed to investigate the effects of different 
culture conditions on MSCs metabolism during adipogenic and osteogenic differentiation 
(42-44). For instance, the addition of L-carnitine during the adipogenic differentiation of 
BMSCs decreased the levels of many saturated and unsaturated long-chain fatty acids, as 
well as the production of metabolites involved in glycolysis, gluconeogenesis, and 
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pyruvate metabolism pathways (45). Based on the culture oxygen levels, Muñoz et al. 
described differences in glutaminolysis, the tricarboxylic acid cycle, and the malate-
aspartate shuttle during the osteogenic differentiation of hBMSCs (43). Finally, the use 
of metabolic profiles as markers of MSCs chondrogenic differentiation has been proposed 
(19).  
In the present work, we have applied for the first time the MALDI-FT-ICR-MSI 
technology to characterize and localize metabolic changes in control and OA hBMSCs 
during the early stages of chondrogenesis. This metabolomic analysis provided key 
findings, including the identification of 35 metabolites significantly altered in the 
differentiation of OA hBMSCs when compared to controls. These metabolites, in 
combination with the 43 proteins differentially regulated in OA chondrogenesis, were 
mapped into several interconnected pathways (Supplemental Figure S9). Remarkably, 
the levels of metabolites involved in the synthesis of UDP-glucuronic synthesis were 
consistently altered in OA cells (Figure 5). In particular, we observed at day 14 an 
accumulation of the precursor UDP-glucose in OA cells compared to controls. A feasible 
reason for this accumulation might be the downregulation of the UGDH enzyme that we 
also detect in this work, in this case by proteomics and gene expression analyses. UGDH 
is required for the conversion of UDP-glucose into UDP-glucuronic acid, thus being 
directly involved in the synthesis of cartilage GAGs and PGs (46). Interestingly, an 
increase of UGDH has been described during ageing and is linked with HA accumulation 
and signaling alterations (47, 48). Other investigations have also demostrated that the 
regulation of UGDH expression levels promotes a marked increase of GAGs and 
enhances chondrogenesis in micromass cultures in vitro (49). In cartilage, UGDH protein 
expression is decreased in the osteoarthritic tissue compared with normal (50). The 
downregulation of UGDH that we report herein may negatively affect the synthesis of 
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UDP-glucuronic acid, and consequently alter the production of ECM PGs and GAGs that 
is required for the proper functionality of cartilage. Moreover, the UDP-glucuronic acid 
can be decarboxylated to UDP-xylose, which is critical for the linking of GAGs to 
proteoglycan core proteins (51). 
Additionally, this work evidences the alteration of the amino sugar metabolism 
(hexosamine pathway) in the chondrogenesis of OA hBMSCs compared to controls. 
Glucosamine (GlcN) is an important amino sugar present in the articular cartilage ECM, 
and also a precursor for GAGs and PG synthesis. Several previous studies have explored 
the effects of GlcN and its derivates, such as GlcNAc, on cartilage repair. These studies 
demonstrated the ability of these molecules to enhance the biosynthesis of relevant 
cartilage PGs and to prevent inflammation by inhibiting the activity of pro-inflammatory 
mediators (52-54). Moreover, GlcN was shown to promote chondrogenesis and stimulate 
GAGs synthesis through the increase of transforming growth factor β1 gene expression 
(55). Additionally, a modified polyethylene glycol hydrogels with GlcN has recently been 
reported to enhance the chondrogenesis of hBMSCs with low fibrosis and expression of 
hypertrophic cartilage markers (56). In our study, the levels of GlcNAc and UDP-GlcNAc 
were significantly decreased in OA hBMSCs after 14 days of differentiation. The 
reduction of these two intermediates may impair HA, PGs and GAGs production. 
Altogether, these results strongly suggest that the UDP-glucuronic acid synthesis pathway 
could serve as a therapeutic target for enhancing cartilage ECM formation in OA.  
Finally, we evaluated the molecular changes undergoing control and OA hBMSCs at day 
2 of chondrogenesis. Our metabolomic analysis demonstrated that ribose-5-phosphate 
and ribose-1,5-bisphosphate are significantly increased in OA, pointing to an enhanced 
activity of the PPP compared to controls. The PPP produces ribose-5-phosphate for the 
novo nucleotide synthesis (57). Our results suggest that OA hBMSCs preferentially use 
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the oxidative branch of this pathway to acquire the ribose-5-phosphate that is essential 
for cell proliferation through DNA and RNA synthesis. This might suggest that OA 
hBMSCs at day 2 could maintain a proliferative stage (specially those cells located at the 
micromass core) compared to controls, which in turn could initiate an early chondrogenic 
differentiation. Altogether, these metabolic alterations detected at the undifferentiated 
state might indicate an earlier upstream dysregulation in the chondrogenic differentiation 
of OA cells. 
In conclusion, our findings reveal a critical role of specific metabolic processes as key 
regulators at the early onset of chondrogenic differentiation. Exploring further these 
pathways is expected to improve understanding on the metabolic regulation of 
chondrogenesis in normal and diseased contexts. Specifically, the alterations in the UDP-
glucuronic acid synthesis pathway reported herein provide novel molecular targets that 
could be investigated for future therapeutic development in diseases affecting the 
cartilage such as OA. 
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Table 1. Chondrogenesis-regulated proteins in OA hBMSCs, identified in this work 
by SILAC and nano-LC-MS/MS analysis. 





Ratio c) p-value EFd) 
Proteins increased at day 14 of chondrogenic differentiation 
Q04446 1,4-alpha-glucan-branching enzyme GBE1 6 2,411 0,005 1,612 
P21589 5'-nucleotidase 5NTD 4 1,559 0,030 1,438 
P15121 Aldose reductase AKR1B1 3 2,779 0,046 EF > 2 
P15144 Aminopeptidase N ANPEP 20 1,637 0,000 1,086 
P07355 Annexin A2 ANXA2 88 1,458 0,000 1,085 
P08758 Annexin A5 ANXA5 50 1,583 0,000 1,096 
P25705 ATP synthase subunit alpha, mitochondrial ATPA 5 1,271 0,042 1,255 
P06576 ATP synthase subunit beta, mitochondrial ATPB 16 1,231 0,024 1,194 
P98160 
Basement membrane-specific heparan sulfate 
proteoglycan core protein or Perlecan 
HSPG2 2 1,940 0,030 1,652 
P12109 Collagen alpha-1(VI) chain COL6A1 8 1,512 0,040 1,480 
P12110 Collagen alpha-2(VI) chain COL6A2 19 1,921 0,000 1,179 
P12111 Collagen alpha-3(VI) chain COL6A3 87 1,866 0,000 1,112 
P14625 Endoplasmin HSP90B1 30 1,514 0,002 1,272 
P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 62 1,362 0,012 1,263 
P62826 GTP-binding nuclear protein Ran RAN 4 2,027 0,011 1,492 
Q9BTM1 Histone H2A type 1-J H2AFJ 11 2,135 0,005 1,572 
P62807 Histone H2B type 1-C/E/F/G/I HIST1H2BC 23 2,516 0,000 1,471 
P62805 Histone H4 HIST1H4A 19 2,518 0,003 1,688 
P00338 L-lactate dehydrogenase A chain LDHA 30 1,545 0,001 1,247 
P07195 L-lactate dehydrogenase B chain LDHB 7 2,099 0,025 1,757 
P43490 Nicotinamide phosphoribosyltransferase NAMPT 4 1,501 0,033 1,507 
P30041 Peroxiredoxin-6 PRDX6 5 1,380 0,032 1,323 
P00558 Phosphoglycerate kinase 1 PGK1 38 1,437 0,048 1,433 
P18669 Phosphoglycerate mutase 1 PGAM1 14 1,402 0,000 1,164 
P02545 Prelamin-A/C LMNA 45 1,420 0,021 1,343 
Q6DRA6 Putative histone H2B type 2-D HIST2H2BD 5 3,595 0,006 1,539 
P46940 Ras GTPase-activating-like protein IQGA1 3 1,938 0,045 1,885 
P04179 Superoxide dismutase [Mn], mitochondrial SOD2 16 2,040 0,002 1,434 
P24821 Tenascin TNC 18 1,756 0,034 1,674 
P29401 Transketolase TKT 4 1,706 0,043 1,631 
P60174 Triosephosphate isomerase TPI1 26 1,530 0,001 1,264 
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O14773 Tripeptidyl-peptidase 1 TPP1 4 1,658 0,006 1,257 
Q16851 UTP-glucose-1-phosphate uridylyltransferase UGP2 2 1,449 0,049 1,443 
Proteins decreased at day 14 of chondrogenic differentiation 
P61981 14-3-3 protein gamma 1433G 10 0,791 0,046 1,254 
P62277 40S ribosomal protein S13 RS13 2 0,601 0,038 1,580 
P13639 Elongation factor 2 EEF2 9 0,682 0,024 1,374 
P21333 Filamin-A FLNA 56 0,509 0,001 1,475 
P13489 Ribonuclease inhibitor RNH1 13 0,239 0,034 EF > 2 
P50454 Serpin H1 SERPINH1 21 0,577 0,002 1,351 
Q9Y490 Talin-1 TLN1 17 0,425 0,017 1,974 
Q01995 Transgelin TAGLN 15 0,171 0,000 EF > 2 
P67936 Tropomyosin alpha-4 chain TPM4 11 0,297 0,001 1,480 
O60701 UDP-glucose 6-dehydrogenase UGDH 11 0,759 0,026 1,255 
a) Protein accession number according to SwissProt and TrEMBL databases. 
b) Number of unique peptides (Pept) used for protein identification at 95% confidence. 
c) Average SILAC ratios (n = 3) that represent the relative protein abundance in hBMSCs 
at day 14 versus day 2 of chondrogenic differentiation.  
d) Error factor (a measure of the error in the average ratio), calculated by Protein Pilot 4.0 
software for quantification accuracy. 
MS = mass spectrometry; LC = liquid-chromatography; SILAC = stable isotope labelling 
by amino acids in cell culture; OA hBMSCs = osteoarthritic human bone marrow 












Figure 1. Chondrogenic differentiation of control and OA hBMSCs. A) 
Immunodetection of aggrecan, B) chondroitin-6-sulfate, C) keratan sulfate, D) collagen 
alpha-1 (II) chain, E) collagen alpha-1 (I) chain and F) collagen alpha-1 (X) chain, 
assessed on control and OA micromasses after 2 and 14 days of chondrogenesis. 
Representative images of the inmunoanalysis (normal, n=4; OA, n=5) are shown in the 
panels (magnification x20). In (A-F), quantitative analysis data are presented as mean 
percentage positivity/ total micromass area ± SEM. *p value <0.05, **p value <0.01, 
***p value <0.001 (Mann Whitney test). C, control; OA, osteoarthritis; 2d, 2 days; 14d, 
14 days. 
Figure 2. Control and OA hBMSCs undergoing chondrogenesis exhibit distinct 
metabolomic features. A, B, E) Histogram score plots of the PCA-DA analysis based 
on metabolomic profiles and discriminating between days 2 and 14 of control hBMSCs 
(A), days 2 and 14 of OA hBMSCs (B), control and OA hBMSCs (E) undergoing 
chondrogenic differentiation. B, D) Discriminant fuction 1 (DF1) spectra loading plots 
showing the discriminating masses between days 2 and 14 of control hBMSCs (B) and 
days 2 and 14 of OA hBMSCs (D) undergoing chondrogenic differentiation. F) 
Discriminant fuction 2 (DF2) spectra loading plot showing the discriminating masses 
between control (days 2 and 14) vs. OA micromasses (days 2 and 14).   
Figure 3. Metabolites altered in OA hBMSCs as a consequence of the chondrogenic 
differentiation process. Levels of 35 metabolites, including phospholipids, were 
significantly altered (p value <0.05) at day 14 when compared to day 2 of chondrogenic 
differentiation. DHAP, dyhidroxyacetone phosphate; PA, phosphatidic acid; CPA, cyclic 
phosphatidic acid; LysoPA, lysophosphatidic acid; P, phosphate; PG, 
phosphatidylglycerol; PI, phosphatidylinositol. 
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Figure 4. Metabolic and integrative pathway analysis overview observed in hBMSCs 
during chondrogenesis. A, B) Metabolic pathways significantly altered in control (A) 
and OA (B) hBMSCs between day 2 and day 14 of chondrogenesis. C, D) Top 10 altered 
pathways observed by integrative pathway analysis for control (C) and OA (D) hBMSCs 
during chondrogenesis. All the matched pathways identified based on overrepresentation 
analysis (ORA) are visualized by circles, with the circle size indicating pathway impact 
(arbitrary scale). The color of the circles indicates unadjusted p values (y axis) from 
pathway enrichment analysis, with red < 0.003; orange < 0.2, and yellow < 0.4 for panel 
A and, red < 0.02; orange < 0.1, and yellow < 0.5 for panel B. The x axis represents 
increasing metabolic pathway impact according to the degree of centrality from topology 
analysis. Terms highlighted with an asterisk were significantly altered (p value < 0.05). 
Figure 5. Spatial distribution and metabolic changes involved in the UDP-glucuronic 
acid interconversion pathway and amino sugar metabolism in OA hBMSCs. A-E) 
MALDI-MSI images showing the abundance and spatial distribution of glucose 
monophosphate (A), UDP-glucose (B), UDP-glucuronic acid (C), N-Acetyl-
glucosamine-phosphate (D) and UDP-N-Acetyl-glucosamine (E) in OA micromasses at 
days 2 (left) and 14 (right) of chondrogenesis. F, G) Gene expression levels determined 
by qRT-PCR of UTP-glucose-1-phosphate uridylyltransferase (F) and UDP-glucose 6-
dehydrogenase (G). In (A-E), data were normalized by root means square. In (F-G), data 
are expressed as mean ± SEM of 5 independent experiments. * p value < 0.05, n.s. not 
significant. 
 
